Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Choy, Edwin ^a   MacConaill, Laura E ^b   Cote, Gregory M ^a   Le, Long P ^a   Shen, Jacson K ^a   Nielsen, Gunnlaugur P ^a   Iafrate, Anthony J ^a   Garraway, Levi A ^b   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALK GENE; ARTICLE; CARCINOGENESIS; CDKN2A GENE; CHORDOMA; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; FEMALE; GENE DELETION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HETEROZYGOSITY LOSS; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; MUTATIONAL ANALYSIS; NRAS GENE; ONCOGENE; PIK3CA GENE; PTEN GENE; SMARCB1 GENE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; CHROMOSOME DELETION; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; TUMOR GENE;

ANAPLASTIC LYMPHOMA KINASE; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NONHISTONE PROTEIN; NRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; PTEN PROTEIN, HUMAN; SMARCB1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CHORDOMA; CHROMOSOMAL PROTEINS, NON-HISTONE; CHROMOSOME DELETION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENES, NEOPLASM; GENOTYPING TECHNIQUES; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTORS;

EID: 84903688653     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101283     Document Type: Article

References (44)

1. Nibu Y, Jose-Edwards DS, Di Gregorio A (2013) From notochord formation to hereditary chordoma: the many roles of Brachyury. Biomed Res Int 2013: 826435.
2. Fernandez-Miranda JC, Gardner PA, Snyderman CH, Devaney KO, Mendenhall WM, et al. (2013) Clival chordomas: A pathological, surgical, and radiotherapeutic review. Head Neck. 36(6):892-906.
3. Koutourousiou M, Snyderman CH, Fernandez-Miranda J, Gardner PA (2011) Skull base chordomas. Otolaryngol Clin North Am 44: 1155-1171.
4. Housari G, Gonzalez M, Calero P, Beni R, Lobo E (2013) Sacral chordoma: management of a rare disease in a tertiary hospital. Clin Transl Oncol 15: 327-330.
5. Lewandrowski KU, Hecht AC, DeLaney TF, Chapman PA, Hornicek FJ, et al. (2004) Anterior spinal arthrodesis with structural cortical allografts and instrumentation for spine tumor surgery. Spine (Phila Pa 1976) 29: 1150-1158; discussion 1159.
6. Di Maio S, Rostomily R, Sekhar LN (2012) Current surgical outcomes for cranial base chordomas: cohort study of 95 patients. Neurosurgery 70: 1355-1360; discussion 1360.
7. Chen YL, Liebsch N, Kobayashi W, Goldberg S, Kirsch D, et al. (2013) Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine (Phila Pa 1976) 38: E930-936.
8. Wagner TD, Kobayashi W, Dean S, Goldberg SI, Kirsch DG, et al. (2009) Combination short-course preoperative irradiation, surgical resection, and reduced-field high-dose postoperative irradiation in the treatment of tumors involving the bone. Int J Radiat Oncol Biol Phys 73: 259-266.
9. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, et al. (2009) Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 74: 732-739.
10. Park L, Delaney TF, Liebsch NJ, Hornicek FJ, Goldberg S, et al. (2006) Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 65: 1514-1521. (Pubitemid 44425209)
11. Smoll NR, Gautschi OP, Radovanovic I, Schaller K, Weber DC (2013) Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer 119: 2029-2037.
12. Schwab JH, Springfield DS, Raskin KA, Mankin HJ, Hornicek FJ (2012) What's new in primary bone tumors. J Bone Joint Surg Am 94: 1913-1919.
13. Bydon M, Papadimitriou K, Witham T, Wolinsky JP, Bydon A, et al. (2012) Novel therapeutic targets in chordoma. Expert Opin Ther Targets 16: 1139-1143.
14. Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH, et al. (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14: 638-647.
15. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. (Pubitemid 38637993)
16. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. (Pubitemid 38720929)
17. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480. (Pubitemid 34879334)
18. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056. (Pubitemid 32267975)
19. Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, et al. (2013) Bone cancer. J Natl Compr Canc Netw 11: 688-723.
20. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
21. Dalpra L, Malgara R, Miozzo M, Riva P, Volonte M, et al. (1999) First cytogenetic study of a recurrent familial chordoma of the clivus. Int J Cancer 81: 24-30. (Pubitemid 29124191)
22. Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, et al. (2001) Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32: 203-211. (Pubitemid 32953974)
23. Mobley BC, McKenney JK, Bangs CD, Callahan K, Yeom KW, et al. (2010) Loss of SMARCB1/INI1 expression in poorly differentiated chordomas. Acta Neuropathol 120: 745-753.
24. Le LP, Nielsen GP, Rosenberg AE, Thomas D, Batten JM, et al. (2011) Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS One 6: e18846.
25. Choy E, Hornicek F, MacConaill L, Harmon D, Tariq Z, et al. (2012) High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 118: 2905-2914.
26. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351. (Pubitemid 46328493)
27. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, et al. (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4: e7887.
28. Kent WJ (2002) BLAT - the BLAST-like alignment tool. Genome Res 12: 656-664.
29. Diaz RJ, Guduk M, Romagnuolo R, Smith CA, Northcott P, et al. (2012) Highresolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis. Neoplasia 14: 788-798.
30. Kadoch C, Crabtree GR (2013) Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 153: 71-85.
31. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, et al. (2013) Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45: 592-601.
32. Wilson BG, Roberts CW (2011) SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11: 481-492.
33. Imbalzano AN, Jones SN (2005) Snf5 tumor suppressor couples chromatin remodeling, checkpoint control, and chromosomal stability. Cancer Cell 7: 294-295. (Pubitemid 40544646)
34. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, et al. (2013) Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 110: 7922-7927.
35. Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, et al. (2010) Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18: 316-328.
36. Seward S, Semaan A, Qazi AM, Gruzdyn OV, Chamala S, et al. (2013) EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53. Cancer Lett 336: 53-60.
37. Alimova I, Birks DK, Harris PS, Knipstein JA, Venkataraman S, et al. (2013) Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol 15: 149-160.
38. Kuwahara Y, Wei D, Durand J, Weissman BE (2013) SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters. Mol Cancer Res 11: 251-260.
39. Yang C, Schwab JH, Schoenfeld AJ, Hornicek FJ, Wood KB, et al. (2009) A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther 8: 2597-2605.
40. Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, et al. (2009) Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res 29: 1867-1871.
41. de Castro Msc CV, Guimaraes G, Aguiar S Jr, Lopes A, Baiocchi G, et al. (2013) Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome. Hum Pathol 44: 1747-1755.
42. Bydon M, Papadimitriou K, Witham T, Wolinsky JP, Bydon A, et al. (2012) Novel therapeutic targets in chordoma. Expert Opin Ther Targets 16: 1139-1143.
43. Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH, et al. (2013) Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther 14: 638-647.
44. El-Khoueiry AB, Ning Y, Yang D, Cole S, Kahn M, et al. (2013) A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol 31 (suppl; abstr 2501).